BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 22642177)

  • 21. Oncolytic parvoviruses as cancer therapeutics.
    Rommelaere J; Geletneky K; Angelova AL; Daeffler L; Dinsart C; Kiprianova I; Schlehofer JR; Raykov Z
    Cytokine Growth Factor Rev; 2010; 21(2-3):185-95. PubMed ID: 20211577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-faceted mechanism of parvoviral oncosuppression.
    Geletneky K; Nüesch JP; Angelova A; Kiprianova I; Rommelaere J
    Curr Opin Virol; 2015 Aug; 13():17-24. PubMed ID: 25841215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncolytic parvoviruses: from basic virology to clinical applications.
    Marchini A; Bonifati S; Scott EM; Angelova AL; Rommelaere J
    Virol J; 2015 Jan; 12():6. PubMed ID: 25630937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virotherapy of digestive tumors with rodent parvovirus: overview and perspectives.
    Akladios C; Aprahamian M
    Expert Opin Biol Ther; 2016; 16(5):645-53. PubMed ID: 26855087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
    Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
    Front Immunol; 2019; 10():1848. PubMed ID: 31440242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncolytic Immunotherapy for Treatment of Cancer.
    Tsun A; Miao XN; Wang CM; Yu DC
    Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
    Bretscher C; Marchini A
    Viruses; 2019 Jun; 11(6):. PubMed ID: 31216641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.
    Cerullo V; Koski A; Vähä-Koskela M; Hemminki A
    Adv Cancer Res; 2012; 115():265-318. PubMed ID: 23021247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
    Sinkovics JG; Horvath JC
    Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Roadmap for the Success of Oncolytic Parvovirus-Based Anticancer Therapies.
    Hartley A; Kavishwar G; Salvato I; Marchini A
    Annu Rev Virol; 2020 Sep; 7(1):537-557. PubMed ID: 32600158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for thoracic oncology gone viral.
    Patel MR
    Immunotherapy; 2018 Apr; 10(5):383-390. PubMed ID: 29473469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review.
    Geletneky K; Herrero Y Calle M; Rommelaere J; Schlehofer JR
    J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):327-30. PubMed ID: 16316394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Oncolytic adenoviruses in anti-cancer therapy: current status and perspectives].
    Sviatchenko VA; Tarasova MV; Netesov SV; Chumakov PM
    Mol Biol (Mosk); 2012; 46(4):556-69. PubMed ID: 23113343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular pathways: rodent parvoviruses--mechanisms of oncolysis and prospects for clinical cancer treatment.
    Nüesch JP; Lacroix J; Marchini A; Rommelaere J
    Clin Cancer Res; 2012 Jul; 18(13):3516-23. PubMed ID: 22566376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients.
    Angelova AL; Geletneky K; Nüesch JP; Rommelaere J
    Front Bioeng Biotechnol; 2015; 3():55. PubMed ID: 25954743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
    Workenhe ST; Verschoor ML; Mossman KL
    Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncolytic virotherapy as a personalized cancer vaccine.
    Li QX; Liu G; Wong-Staal F
    Int J Cancer; 2008 Aug; 123(3):493-9. PubMed ID: 18500742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parvoviral vectors for the gene therapy of cancer.
    Shaughnessy E; Lu D; Chatterjee S; Wong KK
    Semin Oncol; 1996 Feb; 23(1):159-71. PubMed ID: 8607026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncolytic adenoviral therapy for glioblastoma multiforme.
    Sonabend AM; Ulasov IV; Han Y; Lesniak MS
    Neurosurg Focus; 2006 Apr; 20(4):E19. PubMed ID: 16709024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus.
    Brown MC; Gromeier M
    Discov Med; 2015 May; 19(106):359-65. PubMed ID: 26105699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.